Last10K.com

Aerpio Pharmaceuticals, Inc. (ARPO) SEC Filing 8-K Material Event for the period ending Tuesday, August 17, 2021

Aerpio Pharmaceuticals, Inc.

CIK: 1607678 Ticker: ARPO

View differences made from one to another to evaluate Aerpio Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aerpio Pharmaceuticals, Inc..

Continue

Assess how Aerpio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aerpio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Aerpio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ARPO
CIK: 1422142
Form Type: 8-K Corporate News
Accession Number: 0001193125-21-254142
Submitted to the SEC: Mon Aug 23 2021 5:27:04 PM EST
Accepted by the SEC: Mon Aug 23 2021
Period: Tuesday, August 17, 2021
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. New Agreement

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/arpo/0001193125-21-254142.htm